文献速递银屑病与炎症性皮肤病

银屑病、银屑病关节炎与类风湿关节炎患者新发肝病风险:基于人群的队列研究

Risk of Incident Liver Disease in Patients with Psoriasis, Psoriatic Arthritis, and Rheumatoid Arthritis: A Population-Based Study.
PubMed 文献 · J Invest Dermatol · 2017-11-02

该队列研究基于1994–2014年健康改善网络数据,纳入银屑病197,130例、银屑病关节炎12,308例、类风湿关节炎54,251例及匹配对照1,279,754例。结果显示银屑病和银屑病关节炎较类风湿关节炎更易发生肝病,尤其是非酒精性脂肪性肝病和肝硬化,且未接受系统治疗者风险亦升高。

要点

  • 银屑病和银屑病关节炎患者肝病风险高于类风湿关节炎,非酒精性脂肪性肝病和肝硬化风险尤其突出。
  • 未接受系统治疗的银屑病和银屑病关节炎患者肝病风险仍升高。
  • 银屑病皮损体表面积越大,肝病和肝硬化患病率呈阶梯式上升(趋势P<0.001)。

核心结论

  • 银屑病和银屑病关节炎较类风湿关节炎更常与肝病相关,尤其是非酒精性脂肪性肝病和肝硬化,且未接受系统治疗者亦如此。

研究设计与样本

  • 基于健康改善网络1994–2014年的队列研究,纳入银屑病197,130例、银屑病关节炎12,308例、类风湿关节炎54,251例及匹配对照1,279,754例。

主要发现

  • 任何肝病的调整风险比在银屑病未用系统治疗者为1.37、用系统治疗者为1.97,银屑病关节炎未用系统治疗者为1.38、用系统治疗者为1.67,类风湿关节炎未用系统治疗者为1.49,用系统治疗者为0.96。
  • 新发非酒精性脂肪性肝病风险最高见于使用系统治疗的银屑病患者(2.23)和使用系统治疗的银屑病关节炎患者(2.11)。
  • 肝硬化风险最高见于使用系统治疗的银屑病患者(2.62)和未使用系统治疗的银屑病关节炎患者(3.15)。
  • 肝病和肝硬化患病率随银屑病受累体表面积增加呈阶梯式上升(趋势P<0.001)。

临床怎么用

  • 对银屑病和银屑病关节炎患者,即使未接受系统治疗,也应关注肝病风险,尤其非酒精性脂肪性肝病和肝硬化。
  • 银屑病皮损体表面积较大的患者可能需更积极筛查肝病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Relatively little is known about the risk for incident liver disease in psoriasis (PsO), psoriatic arthritis (PsA), and rheumatoid arthritis (RA). We performed a cohort study among patients with PsO, PsA, or RA and matched controls in The Health Improvement Network from 1994 to 2014. Outcomes of interest were any liver disease, nonalcoholic fatty liver disease, and cirrhosis (any etiology). Among patients with PsO (N = 197,130), PsA (N = 12,308), RA (N = 54,251), and matched controls (N = 1,279,754), the adjusted hazard ratios for any liver disease were elevated among patients with PsO (without systemic therapy [ST] 1.37; with ST 1.97), PsA (without ST 1.38; with ST 1.67), and RA without an ST (1.49) but not elevated in patients with RA prescribed an ST (0.96). Incident nonalcoholic fatty liver disease was highest in patients with PsO prescribed an ST (2.23) and PsA with an ST (2.11). The risk of cirrhosis was highest among patients with PsO with an ST (2.62) and PsA without an ST (3.15). Additionally, the prevalence of liver disease and cirrhosis increased in a stepwise fashion with increasing body surface area affected by PsO (P for trend <0.001). More so than RA, PsO and PsA are associated with liver disease, particularly nonalcoholic fatty liver disease and cirrhosis, and this was true even among patients without ST exposure.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Ogdie A, Grewal SK, Noe MH, et al. Risk of Incident Liver Disease in Patients with Psoriasis, Psoriatic Arthritis, and Rheumatoid Arthritis: A Population-Based Study. J Invest Dermatol. 2017. PMID: 29104161. doi:10.1016/j.jid.2017.10.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。